Answers are grounded in this paper and cite their sources.
Lysine-specific demethylase 1 (LSD1) is a crucial epigenetic target closely correlated with the pathological progression of various solid tumors. In recent years, machine learning-driven virtual screening has been increasingly employed in novel drug discovery, providing promising paradigms for the rational development of LSD1 inhibitors. However, efficient screening of LSD1 inhibitors to prioritize candidates for experimental validation is still required. In this study, we propose a virtual screening framework that integrates a classification model, a drug–target affinity (DTA) prediction model (pharma-DTA), molecular docking, and binding free energy calculations. The optimal performance of the classification model is Random Forest with RDKit descriptors, which achieves a high precision of 0.930. The pharma-DTA model was established by integrating features of the ligand, pharmacophore, and the binding pocket of the protein. The model was fine-tuned on the dataset of LSD1 inhibitors, with the mean standard error of predicted pIC50 decreased to 0.5. These models were used to screen potential LSD1 inhibitors from the ZINC library, combined with molecular docking and MM-PBSA binding free energy calculations, and four top hits were identified. This virtual screening framework enables rapid identification of hit compounds for the discovery of potential LSD1 inhibitors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: